OTTAWA, May 21
/PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS;
http://www.htdsmedical.com/) Collagenna Skin care Products has
entered into an exclusive distribution agreement with the Malaysian
company Medimec www.medimec.com.my
Medimec is a company which manufactures birth control devices
which are distributed world wide as well as locally. The company
does not represent any other skin care company and felt that the
Collagenna Product Line was an excellent opportunity for them to
increase revenues locally.
Collagenna CEO Michael Arnkvarn
states :" We are very pleased to team up with such a strong partner
in Malaysia. Dr Rama has built his
business based upon quality before price and this corresponds with
our corporate philosophy. Their products are targeted for women and
we are confident that their contact base will allow them to build a
strong distribution network in a relatively short period of time.
Malaysia is our latest
international partner and we are discussing with several other
potential countries. We are committed to making Collagenna/Melem
Secret a truly International Corporation".
Medimec will carry the full Collagenna Skin Care line as well as
the Melem Secret Nutriceutical line. Products have been sent to
Medimec and have recently been approved for import by the Malaysian
Health authorities. Medimec will shortly have a new website
www.collagen.my which with feature the Collagenna line and the
first major shipment of Collagenna products are scheduled to arrive
in Malaysia on May 22, 2010.
The company reminds our shareholders and followers that the
company does not subscribe to the PinkSheets.Com Filing Service.
Its IR company web site section "CLIENT SUPPORT" TAB
www.minamargroup.net or this direct link
http://minamarmarketinggroup.helpserve.com/ should be reviewed by
its followers for further updates on this and other business
matters. Non-newsworthy events are not press released however
posted on this separate support sites to keep our followers advised
of day-to-day events, and the company corporate web site. For any
matters relating to retail investor queries or to send us the
company directly a message please click on the "INVESTOR SUPPORT"
TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases,
industry updates, and non-weekly activity at the company that may
or may not be news released, please subscribe or opt in mailer at
www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases